US4394502A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunotherapeutic agent for tumors comprising lipopolysaccharide as an active component
Assignee: Individual
•
Filing: 1981-08-18
•
Granted: 1983-07-19
•
Expires: 2001-08-18
Abstract
Abstract Disclosed is a novel immunotherapeutic agent for tumors, which comprises as an active component a lipopolysaccharide derived from human tubercle bacillus or a lipopolysaccharide formed by chemically modifying said lipopolysaccharide.
Inventors
- 👤 Chisato Maruyama
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 03:51
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/02; A61K39/04; A61K31/00; A61K31/70; A61K31/715; A61K39/39; A61P; A61P35/00; A61K2039/555; A61K2039/55511; A61K2039/55572
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
71 words
An immunotherapeutic agent for tumors, which comprises as an effective component lipopolysaccharide comprising, arabinomannan as a polysaccharide and fatty acids bonded to said arabinomannan through an ester linkage, the fatty acid content in said lipopolysaccharide being 3 to 28%, said lipopolysaccharide being obtained by hot water extraction and purification of the cell body of human tubercle bacillus, Mycobacterium tuberculosis strain Aoyama B or Mycobacterium tuberculosis strain H 37 R v .
Claim 2
Dependent Claim
71 words
An immunotherapeutic agent for tumors, which comprises as an effective component lipopolysaccharide comprising, arabinomannan as a polysaccharide and fatty acids bonded to said arabinomannan through an ester linkage, the fatty acid content in said lipopolysaccharide being 3 to 28%, said lipopolysaccharide being obtained by hot water extraction and purification of the cell body of human tubercle bacillus, Mycobacterium tuberculosis strain Aoyama B or Mycobacterium tuberculosis strain H 37 R v .
Claim 3
Dependent Claim
66 words
An immunotherapeutic agent for tumors, which comprises as an effective component lipopolysaccharide prepared by bonding a fatty acid to arabinomannan through an ester linkage, said arabinomannan being obtained by alkali extraction and purification of the cell body of human tubercle bacillus, Mycobacterium tuberculosis strain Aoyama B or Mycobacterium tuberculosis strain H 37 R v , the fatty acid content in said lipopolysaccharide being 3 to 28%.
Claim 4
Dependent Claim
66 words
An immunotherapeutic agent for tumors, which comprises as an effective component lipopolysaccharide prepared by bonding a fatty acid to arabinomannan through an ester linkage, said arabinomannan being obtained by alkali extraction and purification of the cell body of human tubercle bacillus, Mycobacterium tuberculosis strain Aoyama B or Mycobacterium tuberculosis strain H 37 R v , the fatty acid content in said lipopolysaccharide being 3 to 28%.
Claim 5
Dependent Claim
67 words
An immunotherapeutic agent for tumors, which comprises as an effective component lipopolysaccharide prepared by bonding a fatty acid to lipoarabinomannan through an ester linkage, said lipoarabinomannan being obtained by hot water extraction and purification of the cell body of human tubercle bacillus, Mycobacterium tuberculosis strain Aoyama B or Mycobacterium tuberculosis strain H 37 R v , the fatty acid content in said lipopolysaccharide being 3 to 28%.
Claim 6
Dependent Claim
67 words
An immunotherapeutic agent for tumors, which comprises as an effective component lipopolysaccharide prepared by bonding a fatty acid to lipoarabinomannan through an ester linkage, said lipoarabinomannan being obtained by hot water extraction and purification of the cell body of human tubercle bacillus, Mycobacterium tuberculosis strain Aoyama B or Mycobacterium tuberculosis strain H 37 R v , the fatty acid content in said lipopolysaccharide being 3 to 28%.
Claim 7
Dependent Claim
58 words
An immunotherapeutic agent for tumors according to claim 1 wherein said fatty acids are palmitic acid, myristic acid, stearic acid, tuberculostearic acid, heptadecanoic acid, oleic acid and linoleic acid and said lipopolysaccharide has a monosaccharide composition of 30 to 74% of arabinose, 20 to 50% of mannose, 0 to 10% of glucose and 0 to 13% of galactose.
Claim 8
Dependent Claim
55 words
An immunotherapeutic agent for tumors according to claim 2 or 3 wherein fatty acid is selected from the group consisting of palmitic acid and stearic acid and said lipopolysaccharide has a monosaccharide composition of 30 to 74% of arabinose, 20 to 50% of mannose, 0 to 10% of glucose and 0 to 13% of galactose.
References Cited (Backward Citations)
US3600378A
Cited
US3956481A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-07-18 | 1987-01-17 | 1987-07-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-07-18 | 1991-01-17 | 1991-07-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-07-18 | 1995-01-17 | 1995-07-19 | $7700.00 | Window Closed / Lapsed |